Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2020

3 - 8 Dec 2020
Online, Virtual, United States of America
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive ...
Dr Ryotaro Nakamura - City of Hope, California, USA
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive care in older patients with advanced MDS ( Dr Ryotaro Nakamura - City of Hope, California, USA )
17 Feb 2021
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China
Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China ( Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China )
29 Jan 2021
The Burkitt lymphoma international prognostic index
Prof Adam Olszewski - Brown University, Providence, USA
The Burkitt lymphoma international prognostic index ( Prof Adam Olszewski - Brown University, Providence, USA )
24 Dec 2020
Results of venetoclax and azacitidine combination in chemotherapy ineligible unt...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with AML ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL ...
Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA
PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL after commercial tisagenlecleucel ( Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA )
16 Dec 2020
Researchers trace the origin of blood cancer to early childhood, decades before ...
Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK
Researchers trace the origin of blood cancer to early childhood, decades before diagnosis ( Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK )
16 Dec 2020
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...
ASH 2020:  Immunotherapy in relapsed/refractory multiple myeloma ( Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eric Smith )
15 Dec 2020
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patien...
Dr Francesca Gay - University of Torino, Torino, Italy
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial ( Dr Francesca Gay - University of Torino, Torino, Italy )
14 Dec 2020
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosp...
Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine ( Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy )
11 Dec 2020
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multi...
Dr Elena Zamagni - University of Bologna, Bologna, Italy
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma patients ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
10 Dec 2020
Clinical activity and safety of cevostamab in relapsed/refractory multiple myelo...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
10 Dec 2020
ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia
Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany
ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia ( Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany )
10 Dec 2020
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects...
Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM ( Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA )
9 Dec 2020
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukae...
Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Nether...
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of the ITCC-059 study ( Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands )
9 Dec 2020
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab
Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab ( Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands )
9 Dec 2020
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CL...
Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL ( Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA )
9 Dec 2020
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
9 Dec 2020
ASH 2020: Targeted therapies in r/r multiple myeloma
Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar
ASH 2020: Targeted therapies in r/r multiple myeloma ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar )
8 Dec 2020
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment
Prof Monica Bocchia - University of Siena, Siena, Italy
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment ( Prof Monica Bocchia - University of Siena, Siena, Italy )
8 Dec 2020
Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve se...
Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA
Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve settings ( Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA )
8 Dec 2020
Treating acute leukaemias of ambiguous lineage
Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Ho...
Treating acute leukaemias of ambiguous lineage ( Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Hospital, USA )
8 Dec 2020
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China...
Dr Shaji Kumar and Dr Wenming Chen
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective ( Dr Shaji Kumar and Dr Wenming Chen )
8 Dec 2020
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T31...
Dr Jorge Cortes - Augusta University, Augusta, USA
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation ( Dr Jorge Cortes - Augusta University, Augusta, USA )
8 Dec 2020
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combina...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
8 Dec 2020
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin l...
Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )
8 Dec 2020
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
Five year update of ECHELON-1 for classical Hodgkin lymphoma ( Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil )
8 Dec 2020
Off-the-shelf multi-virus specific T cells following haematopoietic stem cell tr...
Dr Bilal Omer - Baylor College of Medicine, Houston, USA
Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation ( Dr Bilal Omer - Baylor College of Medicine, Houston, USA )
8 Dec 2020
Blinatumomab and oral TKIs for the treatment of Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
Blinatumomab and oral TKIs for the treatment of Ph  ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )
8 Dec 2020
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph  ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )
8 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )
8 Dec 2020
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-ye...
Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )
7 Dec 2020
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patien...
Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )
7 Dec 2020
FORTE trial: Impact of minimal residual disease on multiple myeloma patients
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
FORTE trial: Impact of minimal residual disease on multiple myeloma patients ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )
7 Dec 2020
Evaluation of MRD negativity in patients with relapsed or refractory multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
7 Dec 2020
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma
Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma ( Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma
Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma ( Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA )
7 Dec 2020
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in ne...
Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML ( Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA )
7 Dec 2020
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelph...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Trea...
Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )
7 Dec 2020
Predictive factors for overall survival in chronic myeloid leukaemia patients: a...
Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy
Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )
6 Dec 2020
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potent...
Prof David Teachey - The University of Pennsylvania, Rutledge, USA
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL ( Prof David Teachey - The University of Pennsylvania, Rutledge, USA )
6 Dec 2020
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukae...
Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia ( Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA )
5 Dec 2020